181 related articles for article (PubMed ID: 9568638)
41. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF
Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636
[TBL] [Abstract][Full Text] [Related]
42. (-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells.
Shin S; Kim MK; Jung W; Chong Y
Phytother Res; 2018 Oct; 32(10):2086-2096. PubMed ID: 30009577
[TBL] [Abstract][Full Text] [Related]
43. Biphasic regulation of plasminogen activator/inhibitor by LDL in mesangial cells.
Song CY; Kim BC; Hong HK; Kim BK; Kim YS; Lee HS
Am J Physiol Renal Physiol; 2002 Sep; 283(3):F423-30. PubMed ID: 12167592
[TBL] [Abstract][Full Text] [Related]
44. Less is more: low expression of MT1-MMP is optimal to promote migration and tumourigenesis of breast cancer cells.
Cepeda MA; Pelling JJ; Evered CL; Williams KC; Freedman Z; Stan I; Willson JA; Leong HS; Damjanovski S
Mol Cancer; 2016 Oct; 15(1):65. PubMed ID: 27756325
[TBL] [Abstract][Full Text] [Related]
45. Detection of matrix metalloproteinases (MMP), tissue inhibitor of metalloproteinase-2, urokinase and plasminogen activator inhibitor-1 within matrigel and growth factor-reduced matrigel basement membrane.
Gillette KM; Forbes K; Sehgal I
Tumori; 2003; 89(4):421-5. PubMed ID: 14606648
[TBL] [Abstract][Full Text] [Related]
46. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.
Ari F; Napieralski R; Ulukaya E; Dere E; Colling C; Honert K; Krüger A; Kiechle M; Schmitt M
Cell Biochem Funct; 2011 Dec; 29(8):651-9. PubMed ID: 21887697
[TBL] [Abstract][Full Text] [Related]
47. ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1.
Sánchez-Tilló E; de Barrios O; Siles L; Amendola PG; Darling DS; Cuatrecasas M; Castells A; Postigo A
Clin Cancer Res; 2013 Mar; 19(5):1071-82. PubMed ID: 23340304
[TBL] [Abstract][Full Text] [Related]
48. Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.
Siddique K; Yanamandra N; Gujrati M; Dinh D; Rao JS; Olivero W
Int J Oncol; 2003 Feb; 22(2):289-94. PubMed ID: 12527924
[TBL] [Abstract][Full Text] [Related]
49. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
50. Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome.
Witzel ID; Milde-Langosch K; Wirtz RM; Roth C; Ihnen M; Mahner S; Zu Eulenburg C; Jänicke F; Müller V
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1709-18. PubMed ID: 20204407
[TBL] [Abstract][Full Text] [Related]
51. Two transcription factors, E1AF and N-myc, correlate with the invasiveness of neuroblastoma cell lines.
Taguchi K; Yoshida K; Sasaki F; Fujinaga K
Jpn J Cancer Res; 1997 Apr; 88(4):394-400. PubMed ID: 9197532
[TBL] [Abstract][Full Text] [Related]
52. Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells.
Lin CW; Hou WC; Shen SC; Juan SH; Ko CH; Wang LM; Chen YC
Carcinogenesis; 2008 Sep; 29(9):1807-15. PubMed ID: 18628248
[TBL] [Abstract][Full Text] [Related]
53. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
54. Brain-derived neurotrophic factor inducing angiogenesis through modulation of matrix-degrading proteases.
Sun CY; Hu Y; Wang HF; He WJ; Wang YD; Wu T
Chin Med J (Engl); 2006 Apr; 119(7):589-95. PubMed ID: 16620701
[TBL] [Abstract][Full Text] [Related]
55. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
Farabegoli F; Papi A; Orlandi M
Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
[TBL] [Abstract][Full Text] [Related]
56. Mouse trophoblastic cell lines: II--Relationship between invasive potential and proteases.
Sharma RK
In Vivo; 1998; 12(2):209-17. PubMed ID: 9627804
[TBL] [Abstract][Full Text] [Related]
57. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
Bryan L; Paugh BS; Kapitonov D; Wilczynska KM; Alvarez SM; Singh SK; Milstien S; Spiegel S; Kordula T
Mol Cancer Res; 2008 Sep; 6(9):1469-77. PubMed ID: 18819934
[TBL] [Abstract][Full Text] [Related]
58. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer.
Suzuki M; Iizasa T; Fujisawa T; Baba M; Yamaguchi Y; Kimura H; Suzuki H
Invasion Metastasis; 1998-1999; 18(3):134-41. PubMed ID: 10474026
[TBL] [Abstract][Full Text] [Related]
59. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Guo Y; Pakneshan P; Gladu J; Slack A; Szyf M; Rabbani SA
J Biol Chem; 2002 Nov; 277(44):41571-9. PubMed ID: 12198113
[TBL] [Abstract][Full Text] [Related]
60. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]